Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ADC Therapeutics SA (ADCT)

NYSE - NYSE Delayed Price. Currency in USD
3.6200+0.1400 (+4.02%)
At close: 04:00PM EST
3.7600 +0.14 (+3.87%)
After hours: 06:20PM EST
Advertisement
Full screen
Loading interactive chart...
  • Business Wire

    Biocytogen Enters into Antibody Agreement with ADC Therapeutics

    BEIJING, November 28, 2022--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. Biocytogen reserves all global rights for these antibodie

  • Simply Wall St.

    The past year for ADC Therapeutics (NYSE:ADCT) investors has not been profitable

    As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...

  • Zacks

    ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates

    ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -27.45% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Advertisement
Advertisement